EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study

Michihiro Hide, Atsushi Fukunaga, Takayuki Suzuki, Noriko Nakamura, Mine Kimura, Takayoshi Sasajima, Junna Kiriyama, Atsuyuki Igarashi

Allergology International · 2023-04 · 72 (2) · 286-296

DOI: 10.1016/j.alit.2022.09.003 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Allergology International, 2023-04. Verfasst von Michihiro Hide und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Chronic Urticaria, Urticaria, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsChronic UrticariaUrticariaDrug-Related Side Effects and Adverse ReactionsHumansOmalizumabEast Asian PeopleChronic DiseaseProduct Surveillance, PostmarketingTreatment Outcome

Stichwörter der Autor:innen

Chronic spontaneous urticariaJapanOmalizumabReal-worldSafety

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Division of Dermatology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Novartis Pharma K.K., Tokyo, Japan.
  • Novartis Pharma K.K., Tokyo, Japan. Electronic address: junna.kiriyama@novartis.com.
  • Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan.

Zitieren

APA

Hide, M., Fukunaga, A., Suzuki, T., Nakamura, N., Kimura, M., Sasajima, T., Kiriyama, J., & Igarashi, A. (2023). Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study. Allergology International, 72(2), 286-296. https://doi.org/10.1016/j.alit.2022.09.003

Vancouver

Hide M, Fukunaga A, Suzuki T, Nakamura N, Kimura M, Sasajima T, et al. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study. Allergology International. 2023;72(2):286-296. doi:10.1016/j.alit.2022.09.003

BibTeX
@article{Hide2023,
  author = {Hide, Michihiro and Fukunaga, Atsushi and Suzuki, Takayuki and Nakamura, Noriko and Kimura, Mine and Sasajima, Takayoshi and Kiriyama, Junna and Igarashi, Atsuyuki},
  title = {Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study},
  journal = {Allergology International},
  year = {2023},
  volume = {72},
  number = {2},
  pages = {286--296},
  doi = {10.1016/j.alit.2022.09.003}
}
Kostenlos starten →